chr7-117642483-T-C
Variant summary
Our verdict is Pathogenic. The variant received 17 ACMG points: 17P and 0B. PM1PM2PP2PP3_StrongPP5_Very_Strong
The NM_000492.4(CFTR):c.3763T>C(p.Ser1255Pro) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic,drug response (★★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. S1255T) has been classified as Uncertain significance.
Frequency
Consequence
NM_000492.4 missense
Scores
Clinical Significance
Conservation
Publications
- cystic fibrosisInheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Laboratory for Molecular Medicine, Labcorp Genetics (formerly Invitae), Myriad Women’s Health, Orphanet
- congenital bilateral absence of vas deferensInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
- hereditary chronic pancreatitisInheritance: AD Classification: LIMITED Submitted by: Labcorp Genetics (formerly Invitae)
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 17 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| CFTR | NM_000492.4 | c.3763T>C | p.Ser1255Pro | missense_variant | Exon 23 of 27 | ENST00000003084.11 | NP_000483.3 | |
| CFTR-AS2 | NR_199597.1 | n.65+4868A>G | intron_variant | Intron 1 of 2 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Cystic fibrosis Pathogenic:7
The p.S1255P pathogenic mutation (also known as c.3763T>C), located in coding exon 23 of the CFTR gene, results from a T to C substitution at nucleotide position 3763. The serine at codon 1255 is replaced by proline, an amino acid with similar properties. This alteration is considered a class III mutation, meaning it produces a full-length CFTR protein which incorporates normally into the cell membrane, but has defective gating and blocks the flow of chloride ions through the CFTR channel (De Boeck K et al. J. Cyst. Fibros., 2014 Jul;13:403-9). This mutation was identified in a individual diagnosed with cystic fibrosis confirmed with sweat chloride levels in trans with p.F508del (Lissens W et al. Hum. Mol. Genet., 1992 Sep;1:441-2). This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the supporting evidence, this variant is interpreted as a disease-causing mutation. -
- -
- -
This submission and the accompanying classification are no longer maintained by the submitter. For more information on current observations and classification, please contact variantquestions@myriad.com. -
- -
For these reasons, this variant has been classified as Pathogenic. Experimental studies have shown that this missense change affects CFTR function (PMID: 11242048). This sequence change replaces serine, which is neutral and polar, with proline, which is neutral and non-polar, at codon 1255 of the CFTR protein (p.Ser1255Pro). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with cystic fibrosis (PMID: 1284530, 30548586). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 7192). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. -
Variant summary: The CFTR variant, c.3763T>C (p.Ser1255Pro) involves a conserved nucleotide located in the nucleotide-binding domain 2 that 4/4 in silico tools predict damaging outcome. This variant is absent in 121154 ExAC chromosomes. This variant was first found in a Belgian CF patient who was compound heterozygous for this variant and p.Phe508del (Lissens_1992). It has also been reported in another two CF patients without detailed genotype information (Claustres_2000, Schrijver_2016). Currently, it has been reported in 10 CF patients in CFTR2 database. Functional studies have shown that S1255P is defective in channel gating as well as chloride transport (Anderson_1992, Choi_2001, Yu_2012). These defects were shown to be compensated by ivacaftor treatment (Yu_2012). In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as likely pathogenic/pathogenic. Taken together, this variant is classified as pathogenic. -
Hereditary pancreatitis Pathogenic:1
- -
ivacaftor response - Efficacy Other:1
PharmGKB Level of Evidence 1A: Level 1A clinical annotations describe variant-drug combinations that have variant-specific prescribing guidance available in a current clinical guideline annotation or an FDA-approved drug label annotation. Annotations of drug labels or clinical guidelines must give prescribing guidance for specific variants (e.g. CYP2C9*3, HLA-B*57:01) or provide mapping from defined allele functions to diplotypes and phenotypes to be used as supporting evidence for a level 1A clinical annotation. Level 1A clinical annotations must also be supported by at least one publication in addition to a clinical guideline or drug label with variant-specific prescribing guidance. Drug-variant association: Efficacy
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at